|drug3572||VITROS Anti-SARS-CoV-2 IgG test Wiki||1.00|
There is one clinical trial.
All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.
Description: The time between admission to hospital and dischargeMeasure: Duration of Hospitalisation Time: 1 year
Description: The admission of hospitalized patients to the intensive care unit.Measure: The need for ICU Time: 1 year
Description: Mortality rates of patientsMeasure: Mortality Time: 1 year
Description: The presence of lung involvement on thorax CTMeasure: Lung involvement Time: 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports